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Abstract
Objective: To measure (a) the prevalence of problem 
drinking in a population of methadone-treated drug users, 
(b) independent associations with problem drinking, (c) 
the effect of hepatitis C status on drinking behaviour, (d) 
the knowledge of drug users of their hepatitis C status 
and their perception of their drinking behaviour and (e) 
the attitude of drug users to the effect of alcohol on 
hepatitis C virus (HCV) related disease.
Method: A cross sectional survey of 130 drug users in 
treatment at the National Drug Treatment Centre, Dublin 
was carried out. A questionnaire incorporated the Alco-
hol Use Disorders Identification Test (AUDIT), and data 
were collected on sociodemographics, drug use history, 
perceived HCV status and drinking behaviour, and atti-
tudes to the impact of drinking on HCV related disease. 
Hepatitis serology and drug urine data were collected 
from clinical records.
Results: The prevalence of problem drinking was 41% 
(95% CI 33-51%). Unstable accommodation, older age, 
male gender and longer duration of heroin use were 
independent associations with being a problem drinker. 
There was no significant difference in the prevalence of 
problem drinking across HCV status. Knowledge of HCV 
status was accurate, however 35% of those identified as 
AUDIT cases failed to recognise their problem drinking.
Conclusion: HCV infection among Irish drug users 
is compounded by a high prevalence of problem drink-
ing with drug users failing to modify their drinking in 
response. Incorrect perception of problem drinking status 
could be a barrier to addressing this potentially remedi-
able risk factor.
Key words: HCV infection; Alcohol; Methadone; Problem 
drinking.
 
Introduction
In common with many other countries, in Ireland hepatitis 
C virus (HCV) infection is endemic among the drug using 
population. For drug users in contact with treatment services, 
measures of the prevalence of HCV anti-bodies between 
61.8% and 84% have been reported,1,2 and the incidence has 
been estimated to be 66/100 person years at risk.3 Natural 
history studies of HCV infection have estimated progression 
to cirrhosis in up to 24% of HCV infected patients after 20 
years.4 Approximately 170 million people are infected with 
HCV worldwide, comprising approximately 3% of the global 
population,5 and currently, HCV is the most common cause 
of chronic liver disease and liver transplantation in the USA, 
Australia and most of Europe.6-8 
Even conservative predictions estimate that the burden 
of HCV related disease will pose a major challenge for 
most health systems in the future. For example, based on 
age-specific prevalence data from the National Health and 
Nutrition Examination III (NHANES III), it has been estimated 
that in the period 2010-2019, HCV may lead to 720,700 
person years of decompensated cirrhosis and hepatocellular 
carcinoma, with a loss of 1.83 million years of life in those 
under 65 years of age and with a societal cost of $21.3 
million and $54.2 million respectively.9 Similar estimates have 
been produced in France.10 
In Ireland, extrapolating from a cohort of HCV PCR posi-
tive drug users, Kavanagh et al estimated that approximately 
35 cases of hepatocellular carcinoma, 60 cases of hepatic 
decompensation and 50 liver related deaths could be 
expected to occur annually among the Irish opiate dependent 
population.11
Alcohol has been clearly shown to have an independent 
and multiplicative effect on the progression of HCV related 
liver disease,12 even in moderate amounts.13 Indeed, it has 
not been established that there is a ‘safe’ lower limit in those 
who are infected with HCV. To date there have been no stud-
ies published on the drinking response of the Irish drug using 
population to HCV infection. 
The ROSIE (Research Outcome Study in Ireland) study 
examined one year outcomes of a cohort of opiate users in 
treatment. At one year participants reported reductions in 
the use of unprescribed methadone and benzodiazepines, 
heroin, cocaine and crack cocaine but there was no signifi-
cant change in the proportion using alcohol, mean alcohol 
consumption or mean number of days on which alcohol was 
consumed.14 A study conducted on a different cohort to the 
current study, of drug users in treatment in Dublin, used the 
Alcohol Dependence Scale and found a 56% prevalence rate 
of alcohol dependence.15 
Comparison of international data is difficult due to the 
differing criteria used to evaluate drinking behaviour, however 
published studies indicate that problem drinking is a common 
co-morbidity in drug users. Problem drinking prevalence 
between 12% and 42% was reported in two American stud-
ies carried out in the 1970s.16,17 The Tri-State Ethnographic 
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Project subsequently reported a prevalence of 16% of 
‘abusive pattern drinkers’.18 In the UK 39.1% of clients under-
going methadone maintenance were reported to have ‘actual 
or potential drinking problems’ measured by the self-adminis-
tered alcohol screening test (mSAAST).19 Another UK study 
found that 41% of a sample of clients receiving methadone 
maintenance met DSM IV criteria for alcohol dependence.20 
A review of alcohol abuse among people on methadone, by 
Ottomanelli, found that rates ranged from 13-25%.21
Given that alcohol has a detrimental effect on the health 
of those with HCV infection, their drinking behaviour and its 
determinants have an important impact on their HCV-related 
prognosis. Clinicians involved in the treatment of those with 
HCV infection would be keen that those positive for HCV 
would modify their alcohol intake. In the UK McCusker exam-
ined the influence of HCV status on alcohol consumption in 
opiate users in treatment.22 It was found that perceived HCV 
positive status had some impact on drinking behaviour with 
fewer HCV positive than HCV negative clients consuming any 
alcohol in the previous year and more HCV positive clients 
reducing their consumption in the year after diagnosis. 
In order to make a decision to modify drinking, drug users 
must be armed with accurate information regarding their HCV 
status. Though they may be aware of the risks of infection 
associated with their drug use they may not be as certain 
of their own status. Best et al reported that 13.3% of opiate 
users in treatment incorrectly ascertained their HCV status 
and 8.9% were unaware of their status.23
This study aimed to measure the prevalence of prob-
lem drinking, defined as an AUDIT score of eight or more 
in an Irish, opiate dependent sample receiving methadone 
maintenance. Awareness of HCV status and the impact of 
alcohol consumption on HCV related liver disease were also 
evaluated.
Methods
The sampling frame was clients from one of the three 
sectors attending the National Drug Treatment Centre. This is 
the longest established and largest drug treatment service in 
Ireland and is located in the city centre in Dublin. All current 
clients of the sector in the period September to December 
2002 were verbally invited to participate. All participants were 
receiving oral methadone maintenance treatment.
A questionnaire was designed incorporating the AUDIT 
questionnaire, perceived HCV status, perceived drinking 
behaviour and knowledge of the interaction of alcohol with 
HCV liver disease. From clinical records most recent HCV, 
HIV and hepatitis B serology was obtained, and a measure of 
polydrug misuse was constructed by counting the number of 
drug varieties used in the previous year based on urine drug 
screening. 
Clients were also questioned about the age at which they 
first used any drug, the age at which they first used opiates, 
the age they left school and their current accommodation 
status. Accommodation status was classified as roofless (ie. 
sleeping outdoors), unstable (ie. sleeping indoors, but no 
continued tenure over the last month) or stable (ie. sleeping 
indoors with continued tenure for at least one month). 
Participants were asked to respond to the following state-
ments. (a) ‘Alcohol may worsen HCV related liver disease’ 
and (b) ‘Reducing alcohol consumption can help HCV related 
liver disease’. Without prompting, respondents were asked to 
 AUDIT
Characteristic  Total n (%) Case n (%) Non-Case n (%)  p-value†
Gender 
  Male 67 (65.0%) 35 (81.4%) 32 (53.3%) 0.0032 
  Female 36 (35.0%) 8 (18.4%) 28 (46.7%) 
Age (years)* 28 (23-32) 33 (25-38) 27 (23-29) < 0.0001
Age first drug use (years)*  14 (13-16) 14(12-16) 15 (13-16) 0.41
Age first main drug use (years)*  17 (15-22) 16 (15-19) 17 (15-22) 0.14
Years main drug use*  9 (6-15) 16 (8-20) 8 (5-10) < 0.0001
Years any drug use* 12 (9-18)  19 (11-23) 11 (8-15) < 0.0001
Age left school (years)* 15 (14-16) 14 (13-16) 15 (14-16) 0.02
Accommodation 
  Roofless sleeper  9 (8.7%) 7 (16.3%) 2 (3.3%) 0.04 
  Stable 75 (72.9%) 27 (62.3%) 48 (80.0%) 
  Unstable 19 (18.4%)  9 (20.9%) 10 (16.7%)
No. of drugs used 
  1  1 (1.0%)  0 (0%) 1 (1.7%) 0.20 
  2  3 (2.9%) 3 (7.0%) 0 (0.0%) 
  3  5 (4.8%) 3 (7.0%) 2 (3.3%) 
  4 25 (24.3%) 9 (21.0%) 16(26.7%) 
  > 4 69 (67.0%) 28 (65.0%) 41 (68.3%)
*median (interquartile range)  †test characteristic across AUDIT case status
Table 1: The distribution of characteristics across sample stratified by AUDIT status
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self-report their HCV and problem drinker status; this report 
was collected prior to application of the AUDIT tool. The 
same investigator (AN) interviewed all participants.
The Alcohol Use Disorders Identification Test (AUDIT) 
was used to screen for problem drinking. An AUDIT score 
of eight or more was used to define a case. The AUDIT was 
developed from a six-country WHO collaborative project as 
a screening instrument for hazardous and harmful alcohol 
consumption. Eight is taken as the cut off point, as during 
the development of the AUDIT questionnaire, 92% of those 
diagnosed as having hazardous or harmful alcohol use, had a 
score of eight or more, and 94% of those with non-hazardous 
consumption had a score of less than eight.24 The AUDIT has 
been validated for use in a drug dependent population.25  
Data were analysed using the Chi-squared and Kruskall 
Wallis tests. Using a reverse elimination strategy begin-
ning with all significant (p < 0.05) associations on bivariate 
analysis, logistic regression was carried out to determine 
independent associations with problem drinking.
Results
Of the 130 clients in the study population, 103 (79%) 
agreed to participate in the study. The sample consisted of 
67 (65%) men and 36 (35%) women. The median age was 
28 years. Table 1 presents the distribution of sociodemo-
graphic, personal history and drug use history characteristics 
across the group.
Forty-three clients were identified as audit cases indicating 
a problem drinking prevalence in the population of 41% 
(95% CI 33-51%). Bivariate analysis was used to identify 
those characteristics that varied significantly across problem 
drinker status (Table 1). 
Male gender, older age, longer duration of drug use and 
being in accommodation that was not stable, were all signifi-
cant and independent associations with the likelihood of 
being a problem drinker (Table 2).
Eighty-four participants (82% of those surveyed), were 
HCV antibody positive. The prevalence of HCV antibodies 
was not significantly different across problem drinker status 
(81.4% for problem drinkers versus 81.7% for non-problem 
drinkers, p = 0.64). Most of those who were HCV positive 
had no available HCV PCR test results. (Another study of 
Irish drug users in treatment found the prevalence of HCV 
PCR to be 55.7%.11) Table 3 presents these results along 
with the distribution of other viral markers across the study 
group.
Most of the study participants had accurate self-reported 
HCV status; 99% of those who reported their HCV status as 
negative were correct when compared with their most recent 
laboratory records. However, the study group did not perform 
well in correctly self-reporting their problem drinker status. 
Thirty clients regarded their drinking as problematic and 28 
(93%) of these were AUDIT cases. Seventy-three clients 
believed they were not problem drinkers but 15 (21%) were 
AUDIT cases. This means that 35% of those identified by 
the AUDIT tool as having problem drinking did not recognise 
their drinking as such.
Finally, participants were asked two simple questions to 
measure their beliefs about the effect of alcohol on HCV 
disease progression. Most participants agreed that alcohol 
had a negative effect on disease progression and agreed 
Characteristic  AUDIT OR  p-value 
 n (%) (95% CI)
Gender 
  Female 8 (22.2%) 1 
  Male 35 (53.3%) 3.9 0.01 
  (1.4-12.1)
Accommodation 
  Stable 27 (36.6%) 1 
  Other than stable  16 (57.1%) 6.1 0.005 
  (1.9-23.0)
Age (years) 
  < 29 12 (22.6%) 1 
  ≥ 29 29 (63.0%) 4.3 0.03 
  (1.1-17.4)
Main drug use (years) 
  < 10 12 (22.6%) 1  
  ≥ 10 31 (62.0%) 4.9 0.03 
  (1.2-22.9)
Any drug use (years) 
  < 12 11 (25.6%) 1 
  ≥ 12 32 (53.3%) 0.6 0.52 
   (0.2-2.5)
Age left school (years) 
  < 15 24 (52.1%) 1 
  ≥ 15 19 (33.3%) 0.8 0.70 
  (0.3-2.3)
Model parameters: df 6; χ2 38.0; p < 0.001; R square 0.27
Table 2: Logistic regression model to determine independent 
associations with being identified as a problem drinker
 Audit
Characteristic  Total Case Non-Case  p-value† 
 n (%) n (%) n (%)
HCV Ab 
Negative 16 (15.6) 6 (13.9) 10 (16.6) 0.64 
Positive 84 (81.6) 35 (81.4) 49 (81.7) 
Untested   3 (2.8) 2 (4.7) 1 (1.7)
HCV PCR 
Not applicable 16 (15.6) 6 (13.9) 10 (16.6) 0.57 
Negative 4 (3.9) 1 (2.3) 3 (5.0) 
Positive 16 (15.6) 9 (20.9) 7 (11.7) 
Untested 67 (65.0) 27 (62.8) 40 (66.7)
HBsAg 
Negative 92 (89.3) 37 (86.0) 55 (91.7) 0.66 
Positive 9 (8.7) 5 (11.6) 4 (6.7) 
Untested 2 (1.9) 1 (2.3) 1 (1.7)
HIV 
Negative 84 (81.6) 33 (76.7) 51 (85.0) 0.37 
Positive 12 (11.7) 5 (11.6) 7 (11.7) 
Refused 1 (1.0) 1 (2.3) 2 (3.3) 
Untested 6 (5.8) 4 (9.3)
†test characteristic across AUDIT status
Table 3: The distribution of virological results across the sample 
stratified by AUDIT case status
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that reducing alcohol could be beneficial. Of the participants 
101 (98%) agreed that ‘alcohol may worsen HCV related 
liver disease’ and 94 (92%) agreed that ‘reducing alcohol 
consumption may help HCV related liver disease’.
Discussion
Given its impact on HCV-related disease progression, 
moderating or eliminating alcohol consumption is a potentially 
health-promoting response to a diagnosis of HCV infection. 
McCusker found that perceived HCV positive status had 
some influence on alcohol consumption among opiate users 
in treatment.22 The prevalence of HCV infection in our study 
population was high (82%), as was the level of problem drink-
ing (41%). 
It is worrying that the prevalence of HCV infection was not 
lower in the problem drinkers identified in the study popula-
tion as this suggests that these drug users have not adopted 
healthier drinking behaviours in response to their infection. 
There is high awareness of the negative interaction between 
alcohol and hepatitis C so further education in this area is 
unlikely to affect behaviour.
Internationally, excessive alcohol use is recognised as 
a significant co-morbidity for opiate addiction in treat-
ment,19,20,24,26 with prevalence recorded at between 30% 
and 50%. A significant finding in this study was that 35% of 
those who were AUDIT cases failed to identify themselves 
as problem drinkers. This is an area of possible intervention. 
Educational advice may not prove effective, however motiva-
tional interviewing is an alternative approach.
Motivational interviewing is a well studied method of 
counselling, developed by Miller and Rollinick.27 It involves 
helping people recognise and address problems, especially 
those who are reluctant to change and are ambivalent about 
changing. Some of the principles of motivational interview-
ing include the expression of empathy, the development of 
discrepancy between current behaviour and goals and involv-
ing the client actively in the process of problem solving. It has 
been found to be effective as a brief intervention for exces-
sive drinking.28 It has been found to be superior to traditional 
advice giving in the treatment of a broad range of diseases 
and behavioural problems.29 
Motivational interviewing has been found to reduce alco-
hol use among injection drug users with drinking problems.30 
According to the Mesa Grande project, which reviews clini-
cal trials for the treatment of alcohol disorders, the least 
supported interventions are those designed to foster insight, 
educate or confront.31
Conclusion
The independent associations with problem drinking of 
older age, longer duration of drug use, unstable accommoda-
tion and male gender are not necessarily causal and some 
may even be effects, but are still areas of possible interven-
tion. Clinical assessment of drug users should include an 
alcohol use history as decreased awareness can reduce 
harm prevention behaviour on the part, both of the drug user 
and professional. 
Ideally primary prevention strategies would successfully 
prevent people beginning drug use. This remains largely aspi-
rational. Secondary prevention strategies should intervene to 
prevent drug users progressing to injection drug use and, 
if injecting, to prevent sharing injecting equipment. Despite 
secondary prevention strategies HCV infection continues 
to spread.3 Therefore programmes for HCV control in the 
drug using population need to consider tertiary prevention 
strategies which aim to ameliorate risk factors, such as alco-
hol misuse, to reduce disease progression and to improve 
access to effective treatment for infection.
According to a report produced in 2006, Ireland has the 
highest proportion of income spend on alcohol and the high-
est rate of binge drinking in the European Union.33 The SlÁN 
Survey of lifestyles and Nutrition in Ireland in 2003, and more 
recently in 2007, identified 13% and 8% of respondents 
respectively as drinking more than the recommended weekly 
limit.34,35 A paper on the psychological health and wellbe-
ing of young Irish adults whose average age was 21, found 
that 22% had a likely diagnosis of alcohol dependence yet 
none of the participants in this study classified themselves as 
heavy drinkers and 55% regarded themselves as moderate 
drinkers.36 
The Alcohol Aware Practice Pilot was the first national 
study on alcohol in primary care.37 It found that 16% of the 
study population had hazardous drinking and 3% had harmful 
drinking, based on AUDIT scores.
The problem drinking of those positive for HCV must be 
considered in the wider societal context. The high level of 
alcohol consumption in Ireland in general, makes it even 
more challenging to target this high risk group, however, as 
problem drinking is a potentially remediable factor for HCV 
progression it is a worthwhile undertaking.
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